1030206--2/2/2010--VASCULAR_SOLUTIONS_INC

related topics
{product, liability, claim}
{product, market, service}
{stock, price, operating}
{operation, natural, condition}
{control, financial, internal}
{product, candidate, development}
{regulation, government, change}
The risks and uncertainties described below are not the only ones facing our company. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations. If any of the following risks occur, our business, financial condition or results of operations could be seriously harmed. We will not be successful if the interventional medical device community does not adopt our new products. We have a limited history of profitability and may not be profitable in the future. We are involved in and may face additional litigation claims which could prevent us from manufacturing and selling our products or result in our incurring substantial costs and liabilities. Our future operating results are difficult to predict and may vary significantly from quarter to quarter, which may adversely affect the price of our common stock. We may face product liability claims that could result in costly litigation and significant liabilities. The market for interventional medical devices is highly competitive and will likely become more competitive, and our competitors may be able to respond more quickly to new or emerging technologies and changes in customer requirements that may render our products obsolete. Our international sales are subject to a number of risks that could seriously harm our ability to successfully commercialize our products in any international market. Our business and results of operations may be seriously harmed by changes in third-party reimbursement policies. Our products and our manufacturing activities are subject to extensive governmental regulation that could prevent us from selling our products in the United States or introducing new and improved products.

Full 10-K form ▸

related documents
1030206--2/5/2008--VASCULAR_SOLUTIONS_INC
1030206--2/3/2009--VASCULAR_SOLUTIONS_INC
918112--8/31/2009--NEUROBIOLOGICAL_TECHNOLOGIES_INC_/CA/
918112--9/28/2010--NEUROBIOLOGICAL_TECHNOLOGIES_INC_/CA/
1091596--2/26/2007--CYTOMEDIX_INC
874716--2/27/2008--IDEXX_LABORATORIES_INC_/DE
882873--9/20/2007--UROLOGIX_INC
793279--9/13/2007--CANDELA_CORP_/DE/
793279--9/13/2006--CANDELA_CORP_/DE/
816284--2/18/2010--CELGENE_CORP_/DE/
793279--9/11/2008--CANDELA_CORP_/DE/
1068874--10/12/2006--IMPLANT_SCIENCES_CORP
811669--2/23/2007--UST_INC
10081--8/30/2006--BARR_PHARMACEUTICALS_INC
1050007--11/29/2007--NUTRACEUTICAL_INTERNATIONAL_CORP
1006195--6/8/2009--MATRIXX_INITIATIVES_INC
1347022--2/12/2009--VeriChip_CORP
776008--3/14/2006--STAR_SCIENTIFIC_INC
1104280--12/3/2010--SANGUI_BIOTECH_INTERNATIONAL_INC
59440--3/16/2007--VECTOR_GROUP_LTD
793279--10/1/2009--CANDELA_CORP_/DE/
882873--9/21/2009--UROLOGIX_INC
1050007--11/20/2008--NUTRACEUTICAL_INTERNATIONAL_CORP
893160--2/16/2007--VENTANA_MEDICAL_SYSTEMS_INC
1050007--12/10/2009--NUTRACEUTICAL_INTERNATIONAL_CORP
1050007--11/23/2010--NUTRACEUTICAL_INTERNATIONAL_CORP
874710--9/26/2008--ALLIED_HEALTHCARE_PRODUCTS_INC
886163--3/16/2007--LIGAND_PHARMACEUTICALS_INC
1013606--3/12/2007--ENDOLOGIX_INC_/DE/
1013606--3/16/2006--ENDOLOGIX_INC_/DE/